Consolidated Balance Sheets Statement - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
CURRENT ASSETS:
Cash and cash equivalents	$ 14,342	$ 14,764
Accounts receivable, net of allowance for doubtful accounts of $3,133 and $3,139 at 2017 and 2016, respectively	121,810	114,329
Inventories	37,537	33,720
Prepaid expenses	12,251	10,711
Income taxes receivable	8,738	6,426
Other current assets	6,303	6,511
TOTAL CURRENT ASSETS	200,981	186,461
PROPERTY, PLANT AND EQUIPMENT, net	127,728	129,882
INTANGIBLES, net	9,813	9,936
GOODWILL	179,044	179,044
DEFERRED TAX ASSETS, net	15,194	20,605
OTHER ASSETS	47,656	47,124
TOTAL ASSETS	580,416	573,052
CURRENT LIABILITIES:
Accounts payable	36,477	33,720
Accrued payroll and related costs	24,986	19,411
Taxes other than payroll and income	6,373	5,816
Unearned revenue	19,300	15,690
Income taxes payable	11,432	15,718
Other current liabilities	10,229	13,668
TOTAL CURRENT LIABILITIES	108,797	104,023
LONG-TERM DEBT, net	218,613	216,488
DEFERRED COMPENSATION	47,736	46,251
DEFERRED TAX LIABILITIES, net	7,469	6,277
OTHER LONG-TERM LIABILITIES	44,454	44,716
COMMITMENTS AND CONTINGENCIES (Note 6)
Preference shares, EUR 0.02 par value; 6,000,000 shares authorized, none issued or outstanding	0	0
Common shares, EUR 0.02 par value; 200,000,000 shares authorized, 44,796,252 issued and 44,175,731 outstanding at 2017 and 44,796,252 issued and 44,151,261 outstanding at 2016	1,148	1,148
Additional paid-in capital	54,440	52,850
Retained earnings	181,247	187,957
Accumulated other comprehensive income (loss)	(9,599)	(9,828)
Treasury shares (at cost), 620,521 at 2017 and 644,991 at 2016	(77,829)	(80,773)
Total Core Laboratories N.V. shareholders' equity	149,407	151,354
Non-controlling interest	3,940	3,943
TOTAL EQUITY	153,347	155,297
TOTAL LIABILITIES AND EQUITY	$ 580,416	$ 573,052